Antisense and RNAi Therapeutics Market By Therapeutic Type (Antisense Oligonucleotides, RNA Interference); By Application (Genetic Disorders, Oncology, Neurodegenerative Diseases, Ophthalmology, Infectious Diseases); By Route of Administration (Intravenous, Subcutaneous, Intrathecal, Others); By End User (Biopharmaceutical Companies, Hospitals, Specialty Clinics, Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Antisense and RNAi Therapeutics Market Expands Beyond Rare Disease as ATTR and Lipid Drugs Build Billion-Dollar Franchises

The Global Antisense and RNAi Therapeutics Market is estimated to reach USD 6.81 billion in 2025 and is projected to grow to USD 20.93 billion by 2032, expanding at a CAGR of 17.4%, supported by precision medicine, RNA interference, gene silencing, clinical pipeline expansion, and rare disease applications, according to Strategic Market Research.

 

The antisense and RNAi therapeutics market has progressed from a small group of orphan medicines into a commercially established specialty-pharmaceutical category. An analyst roll-forward of U.S. Food and Drug Administration records identifies 21 cumulative FDA-approved antisense oligonucleotide and siRNA therapeutics through July 2026—13 ASOs and eight siRNAs—compared with the FDA’s count of 17 products in July 2024. The cumulative figure includes historical products that have been withdrawn or discontinued, so it should not be interpreted as the number of therapies actively commercialized in every country. (U.S. Food and Drug Administration)

 

Selected publicly disclosed product sales provide a more useful measure of commercial maturity. Alnylam’s marketed RNAi portfolio, Leqvio, Spinraza, Qalsody, Sarepta’s exon-skipping PMO franchise, Tryngolza, Dawnzera, Wainua and Rytelo collectively generated approximately USD 7.3 billion in reported 2025 product sales. The calculation is a commercial revenue floor rather than a complete market-size estimate because several products do not disclose annual sales separately and country-level net prices, rebates and treatment volumes remain confidential. (SEC)

 

Market Scope and Commercial Logic

The market covers therapeutics that bind disease-relevant RNA and alter protein production through antisense or RNA-interference pathways. ASOs can reduce RNA, modify splicing or block translation, while siRNA products use cellular RNA-interference machinery to degrade targeted messenger RNA. The report excludes mRNA vaccines, aptamers, gene-editing medicines, research reagents and non-therapeutic nucleic-acid products. (Drug Discovery News)

Commercial differentiation depends less on the basic gene-silencing concept and more on tissue delivery, target selection, duration of effect, safety monitoring and administration burden. Liver-directed GalNAc conjugation has produced the largest approved siRNA portfolio because hepatocyte delivery is comparatively well established. CNS and muscle delivery remain more difficult, although intrathecal ASOs and emerging extrahepatic RNAi platforms are widening the addressable indication range.

FDA guidance notes that oligonucleotide therapeutics often have a comparatively long pharmacodynamic effect even when circulating pharmacokinetic half-lives are shorter. Longer target suppression has supported dosing schedules ranging from monthly administration to quarterly or twice-yearly maintenance, creating a persistence and convenience advantage over therapies that require daily or weekly use. Chemistry, conjugation and organ distribution still require product-specific assessment rather than class-wide assumptions. (U.S. Food and Drug Administration)

 

Antisense and RNAi Therapeutics Market Segment Breakdown, 2025–2032

The principal revenue anchors include Alnylam’s USD 2.99 billion RNAi portfolio, Leqvio’s USD 1.198 billion sales, Spinraza’s USD 1.547 billion, Qalsody’s USD 86.9 million, Sarepta’s USD 965.6 million PMO franchise and Tryngolza’s USD 108 million first-year sales. These product-level figures were normalized against SMR’s USD 6.81 billion market total because company disclosures can differ in scope, reporting geography, partnership accounting and product classification.

The model also uses the approval, patient-demand and commercialization evidence compiled in the supporting research database.

 

RNAi Therapeutics Hold the Larger Modality Share

Small-interfering RNA therapeutics are estimated to account for 57.0% of the market in 2025, equivalent to approximately USD 3.88 billion. Alnylam’s four commercial RNAi products generated USD 2.99 billion in 2025, while Novartis reported USD 1.198 billion from Leqvio. Qfitlia and Redemplo add new hemophilia and triglyceride-reduction revenue streams, although their 2025 contributions were limited by partial-year launches.

RNAi therapeutics are projected to increase their share to 64.0% by 2032, creating an estimated USD 13.40 billion segment. Growth is supported by less-frequent GalNAc-conjugated products, expansion into ATTR cardiomyopathy, hypercholesterolemia, hypertension and severe hypertriglyceridemia, and the development of delivery platforms targeting adipose tissue, skeletal muscle and the central nervous system.

Antisense oligonucleotides retain a substantial 43.0% share in 2025, supported by Spinraza, Sarepta’s exon-skipping medicines, Qalsody, Wainua, Tryngolza, Dawnzera and other marketed products. Spinraza and Sarepta’s PMO portfolio alone generated more than USD 2.5 billion in 2025.

 

Rare Genetic and Neuromuscular Diseases Lead the 2025 Market

Rare genetic and neuromuscular diseases are estimated to represent 42.5% of 2025 revenue, or approximately USD 2.89 billion. The segment includes spinal muscular atrophy, Duchenne muscular dystrophy, hereditary ATTR polyneuropathy and other mutation-defined disorders.

Spinraza generated USD 1.547 billion in 2025, while Sarepta’s Exondys 51, Vyondys 53 and Amondys 45 portfolio generated USD 965.6 million. These products maintain high per-patient value but face slower volume expansion because treatment is limited by genetic eligibility, small patient populations and competing gene therapies.

 

Cardiovascular and Metabolic Disorders Become the Largest Segment by 2032

Cardiovascular and metabolic disorders are estimated to account for 38.2% of 2025 revenue, equivalent to USD 2.60 billion. This calculation includes Leqvio, the cardiomyopathy-associated portion of Amvuttra revenue, Tryngolza, emerging Redemplo revenue and other cardiometabolic RNA therapies.

The segment is projected to reach USD 9.42 billion by 2032, representing 45.0% of the total market. Its estimated 20.2% CAGR reflects expansion into ATTR cardiomyopathy, hypertension, severe hypertriglyceridemia, lipoprotein(a)-associated cardiovascular disease, obesity and broader lipid management.

 

Neurology Records the Strongest Pipeline-Led Expansion

Neurological disorders account for a relatively small 2.5% share in 2025, led by Qalsody and early commercial RNA-targeted neurology products. The segment is projected to reach 7.0% by 2032, supported by programs targeting Angelman syndrome, Huntington’s disease, Alzheimer’s disease, tau-related disorders, FUS-associated ALS and other genetically defined neurological conditions.

The estimated 36.0% CAGR is highly sensitive to clinical success, regulatory approval and CNS-delivery performance. It should be presented as a modeled scenario rather than a published segment forecast.

 

 Subcutaneous Products Account for 60.5% of 2025 Revenue

Subcutaneous administration is estimated to generate USD 4.12 billion in 2025, representing 60.5% of the market. The segment includes Amvuttra, Givlaari, Oxlumo, Leqvio, Wainua, Tryngolza, Dawnzera, Qfitlia and Redemplo.

Its share is projected to reach 70.0% by 2032, supported by GalNAc conjugation, prefilled syringes, autoinjectors, home-capable administration and dosing intervals ranging from monthly to twice yearly. Less-frequent subcutaneous administration also reduces the dependence on infusion capacity that restricts intravenous and intrathecal products.

 

Intrathecal Revenue Remains Concentrated in Two Major Franchises

Intrathecal administration is estimated to hold a 22.0% share in 2025, equivalent to USD 1.50 billion. Spinraza and Qalsody account for most of this revenue. Spinraza alone generated USD 1.547 billion in 2025, although part of its reported revenue is normalized within the overall market model.

The intrathecal segment continues growing in absolute terms but declines to 14.5% of total market revenue by 2032 as subcutaneous products enter larger cardiovascular and metabolic populations.

Intravenous Products Maintain Specialist-Center Demand

The intravenous segment is estimated at 17.5% in 2025, supported principally by Sarepta’s weekly DMD exon-skipping products and Onpattro. Intravenous delivery remains relevant for hospital-administered neuromuscular and hematology products but faces pressure from less-frequent subcutaneous formulations.

 

Hospital Pharmacies Lead the Base-Year Market

Hospital pharmacies are estimated to account for 51.0% of 2025 revenue, or approximately USD 3.47 billion. Spinraza, Qalsody, Sarepta’s DMD medicines, Onpattro and several healthcare-professional-administered products require hospitals, specialist centers, infusion facilities or physician-supervised administration.

Specialty Pharmacies Overtake Hospital Pharmacies by 2032

Specialty pharmacies are projected to increase from 45.0% in 2025 to 51.5% by 2032, reaching approximately USD 10.78 billion. Expansion is supported by self-administered and home-capable products, including Wainua, Tryngolza, Dawnzera and Redemplo, along with future subcutaneous cardiometabolic and neurological therapies.

Retail and online specialty channels remain comparatively small because these products require cold-chain handling, prior authorization, patient-support programs and specialist prescriptions. The category includes accredited mail-order specialty channels rather than conventional open online retailing.

 

North America Accounts for 57.5% of the 2025 Market

North America is estimated to generate USD 3.92 billion in 2025, representing 57.5% of global revenue. The region benefits from the deepest approval base, higher specialty-drug net prices, established genetic-testing pathways, extensive specialist networks and comparatively rapid uptake of newly approved therapies.

Alnylam generated approximately 69% of its 2025 product revenue in the United States, based on reported sales for Amvuttra, Onpattro, Givlaari and Oxlumo. Sarepta’s PMO business is also strongly concentrated in the U.S. market. In contrast, Spinraza and Qalsody have meaningful international revenue, preventing the total market from becoming as U.S.-concentrated as Alnylam’s portfolio.

North America remains the largest region in 2032 but its share falls to 49.0% as regulatory approvals and reimbursement expand across Asia-Pacific and emerging markets.

 

Europe Holds a 25.0% Base-Year Share

Europe is estimated to represent 25.0% of 2025 revenue, equivalent to USD 1.70 billion. Centralized regulatory authorization supports multi-country market entry, but national health-technology assessments, confidential rebates and managed-access agreements slow conversion from approval to paid treatment.

The region is projected to reach USD 5.02 billion by 2032, while its market share remains relatively stable at 24.0%.

 

Asia-Pacific Becomes the Fastest-Growing Commercially Meaningful Region

Asia-Pacific is estimated to increase from USD 885 million in 2025 to USD 4.19 billion by 2032, representing a modeled CAGR of 24.8%. Growth is supported by Japanese demand for SMA and DMD medicines, new approvals in China and Australia, improving rare-disease diagnosis and multinational licensing partnerships.

China, Japan and Australia are expected to account for most regional revenue, while India, South Korea and Southeast Asian markets contribute through selective reimbursement and private specialty-care channels.

 

ATTR Amyloidosis Has Become the Largest Verified Revenue Pool

Transthyretin amyloidosis currently represents the most commercially important RNA-silencing franchise. Alnylam reported USD 2.314 billion in 2025 Amvuttra revenue, compared with USD 970 million in 2024. Onpattro generated another USD 173 million, taking Alnylam’s combined TTR revenue to approximately USD 2.49 billion. Growth accelerated after Amvuttra received an expanded indication for transthyretin amyloid cardiomyopathy, moving the product beyond hereditary polyneuropathy into a larger cardiology population. (SEC)

Amvuttra and Onpattro produced USD 910 million in the first quarter of 2026, up 153% year over year, with Amvuttra contributing USD 890 million. Alnylam maintained 2026 TTR revenue guidance of USD 4.4–4.7 billion and reported strong adherence to quarterly healthcare-professional administration. Earlier diagnosis and specialist referral are now central to franchise growth, reflected in Alnylam’s collaborations with Viz.ai and the American Heart Association to improve ATTR-CM identification and care coordination. (Alnylam Investor Relations)

Competition is increasing across both modalities. Wainua, the self-administered eplontersen ASO developed by Ionis and AstraZeneca, generated USD 212 million in partner-reported 2025 sales for hereditary ATTR polyneuropathy. Ionis and AstraZeneca are also studying eplontersen in ATTR cardiomyopathy, while Alnylam is advancing nucresiran through Phase III studies in ATTR-CM and hereditary ATTR polyneuropathy. Successful cardiomyopathy data would place another ASO against established RNAi silencers and transthyretin stabilizers. (Ionis Pharmaceuticals, Inc.)

 

Cardiometabolic Expansion Changes the Market’s Volume Ceiling

Inclisiran established the first large-population RNAi franchise outside rare disease. Novartis reported USD 1.198 billion in 2025 Leqvio sales, representing 59% reported growth. Its twice-yearly maintenance schedule creates a differentiated treatment model for patients requiring additional LDL cholesterol reduction, but realized demand remains dependent on physician-administered workflows, medical-benefit reimbursement and treatment eligibility. (Novartis)

Approximately 86 million U.S. adults had total cholesterol above 200 mg/dL in the 2017–2020 dataset cited by the CDC, while almost 25 million exceeded 240 mg/dL. These figures are epidemiological ceilings rather than inclisiran-eligible patient totals. Clinical risk, prior lipid-lowering therapy, adherence, insurance authorization and physician preference remove a large share of the broad population before treatment begins. (CDC)

The next cardiometabolic growth wave is moving toward hypertension, triglyceride disorders, obesity and multi-target lipid control. Alnylam and Roche initiated the Phase III ZENITH cardiovascular-outcomes trial of zilebesiran in patients with uncontrolled hypertension and high cardiovascular risk. The program is designed around twice-yearly dosing and is expected to enroll approximately 11,000 patients across more than 30 countries, giving RNAi its largest late-stage test in a common chronic disease. (Alnylam Investor Relations)

Triglyceride reduction has already created direct ASO-versus-siRNA competition. Tryngolza, an apoC-III-directed ASO, generated USD 108 million in its first full commercial year in 2025 and received an expanded U.S. indication in June 2026 for adults with severe hypertriglyceridemia, including reduction of acute-pancreatitis risk. The broader label substantially increases Ionis’s addressable population beyond ultra-rare familial chylomicronemia syndrome. (Ionis Pharmaceuticals, Inc.)

Arrowhead launched the competing siRNA Redemplo for familial chylomicronemia syndrome in November 2025. The company reported more than 400 prescriptions written by May 2026, including patients switching from another apoC-III inhibitor, while noting that written prescriptions still require payer adjudication before becoming paid claims. Arrowhead set a U.S. wholesale acquisition cost of USD 45,000 per patient annually under a unified pricing model intended to cover current and potential future indications.

Familial chylomicronemia syndrome affects an estimated 1–13 people per million in the United States, creating an extremely limited patient pool despite premium orphan-drug economics. Competition between Tryngolza and Redemplo will therefore be determined by diagnosis rates, triglyceride reduction, pancreatitis outcomes, dosing convenience, payer contracting and switching rather than broad population growth. (FDA Access Data)

 

Rare Neuromuscular Diseases Retain High Per-Patient Value

Spinraza remains the largest ASO franchise in neurology. Biogen reported USD 1.547 billion in 2025 revenue, down approximately 2% from 2024 but still demonstrating durable maintenance demand nearly a decade after its initial approval. A new high-dose regimen provides lifecycle-management potential as Spinraza competes with oral risdiplam and one-time gene therapy. (SEC)

The estimated U.S. incidence of spinal muscular atrophy is approximately one in 11,000 births. Newborn screening creates a recurring flow of patients who can be identified before irreversible motor-neuron loss, although treatment choice is now divided among multiple disease-modifying modalities. Early diagnosis benefits the total SMA treatment category but does not guarantee continued Spinraza leadership. (HRSA)

Duchenne muscular dystrophy exon-skipping therapies generated another major ASO revenue pool. Sarepta’s Exondys 51, Vyondys 53 and Amondys 45 franchise recorded USD 965.6 million in 2025 PMO revenue. Each product addresses a mutation-defined subgroup rather than the entire DMD population, placing genetic testing, specialist referral and exon eligibility at the center of commercial conversion. Sarepta is also developing five clinical-stage RNAi programs across myotonic dystrophy, facioscapulohumeral muscular dystrophy, Huntington’s disease, idiopathic pulmonary fibrosis and spinocerebellar ataxias, extending the company beyond exon-skipping ASOs. (Sarepta Therapeutics, Inc.)

Qalsody generated USD 86.9 million in 2025 for SOD1-associated amyotrophic lateral sclerosis. Its accelerated approval was based on reduction in plasma neurofilament light chain, leaving confirmatory evidence important for long-term regulatory and payer confidence. The product illustrates both the pricing potential and commercial limitation of therapies restricted to a small genetically confirmed subgroup. (SEC)

 

Hematology, Hereditary Angioedema and Oncology Add New Revenue Channels

Sanofi’s Qfitlia expanded RNAi into prophylactic hemophilia treatment in March 2025. Its label covers patients aged 12 years and older with hemophilia A or B, with or without inhibitors. The CDC estimates that as many as 33,000 males live with hemophilia in the United States, but Qfitlia’s addressable population is narrowed by age, prophylaxis choice, competing non-factor products, gene therapy and mandatory antithrombin monitoring. (U.S. Food and Drug Administration)

Qfitlia’s individualized dosing requires an FDA-cleared antithrombin activity assay, connecting commercial adoption to specialist centers, laboratory infrastructure and continued patient monitoring. Lower dosing frequency can reduce treatment burden, while testing requirements and risk-management procedures increase provider workload and may slow initiation. (FDA Access Data)

Dawnzera introduced ASO prophylaxis for hereditary angioedema in August 2025. Ionis reported USD 8 million in 2025 net sales, including USD 7 million during the fourth quarter, and subsequently secured European authorization. Home-capable dosing every four or eight weeks offers a convenience-based position in a market already served by injectable monoclonal antibodies, kallikrein inhibitors and oral prophylactic therapy. (FDA Access Data)

Rytelo extends oligonucleotide commercialization into oncology and hematology. Geron reported USD 183.6 million in 2025 revenue from the telomerase-targeting oligonucleotide, supported by approximately 1,300 ordering accounts by year-end. Its four-week intravenous administration creates a hospital and infusion-center revenue pathway that differs from self-administered GalNAc-conjugated products. (Geron Corporation)

 

Pipeline Value Is Shifting Toward Larger Diseases and Extrahepatic Delivery

Alnylam’s late-stage portfolio includes zilebesiran in hypertension and nucresiran in ATTR amyloidosis. Earlier programs target cerebral amyloid angiopathy, Alzheimer’s disease, Huntington’s disease, type 2 diabetes, obesity and bleeding disorders. The company’s development strategy pairs established liver delivery with newer CNS and adipose-tissue platforms, reducing dependence on rare hepatic targets. (Alnylam Investor Relations)

Ionis is advancing obudanersen in Phase III development for Angelman syndrome, pelacarsen for lipoprotein(a)-associated cardiovascular disease, eplontersen for ATTR cardiomyopathy, ulefnersen for FUS-associated ALS and salanersen as a next-generation SMA program. Obudanersen’s Phase III enrollment and the expected cardiovascular data for pelacarsen and eplontersen represent major category events because positive results could open sizeable new neurology and cardiology markets. (Ionis Pharmaceuticals, Inc.)

Arrowhead’s development portfolio includes a dual-target RNAi candidate designed to silence PCSK9 and APOC3 simultaneously, adipose-targeted obesity programs and ARO-MAPT for tau-related neurodegenerative diseases. The company also licensed its preclinical alpha-synuclein program to Novartis for USD 200 million upfront and potential development, regulatory and commercial milestones of up to USD 2 billion. Partnerships of this scale indicate that extrahepatic delivery and CNS penetration are becoming major strategic assets rather than research-stage options. (Arrowhead Pharmaceuticals Inc.)

 

Manufacturing Scale Becomes More Important as Patient Populations Expand

Rare-disease production volumes allowed early oligonucleotide products to operate within specialized manufacturing networks. Cardiovascular and metabolic indications require larger batch capacity, lower cost per dose, more consistent conjugation and dependable global supply.

Alnylam announced a USD 250 million expansion of its Massachusetts manufacturing facility to create a dedicated enzymatic-ligation platform for siRNA production. The company expects the investment to expand capacity and lower production costs as its portfolio moves toward hypertension, obesity, diabetes and additional high-volume indications. Manufacturing efficiency will increasingly influence gross margins and launch readiness as RNA therapeutics compete with mature biologics and inexpensive oral medicines. (SEC)

 

Regional Commercial Positioning

North America has the deepest verified commercial base, supported by the cumulative FDA approval record, concentrated specialty-pharmaceutical infrastructure and rapid uptake of ATTR, lipid, neuromuscular and hematology products. The United States has also become the primary launch market for Tryngolza, Redemplo, Qfitlia, Dawnzera and Rytelo. No reliable public dataset supports assigning a precise North American market share.

Europe offers a large reimbursed opportunity but requires country-level health-technology assessment and price negotiation after centralized authorization. Managed-access agreements can accelerate treatment availability while imposing evidence-generation, eligibility and pricing conditions. Tryngolza and Redemplo now create direct ASO–siRNA competition in European FCS treatment. (Ionis Pharmaceuticals, Inc.)

Asia-Pacific is gaining importance through established Japanese demand for DMD therapies, Chinese approvals and multinational licensing arrangements. Redemplo has secured approvals in China and Australia, with Sanofi responsible for Greater China commercialization. Wainua has also expanded into China, while Japan remains an important market for Spinraza and Viltepso. (Arrowhead Pharmaceuticals Inc.)

 

Strategic Commercial Opportunity

The strongest current revenue opportunity remains ATTR amyloidosis, where Amvuttra’s cardiomyopathy expansion has produced rapid demand growth. Cardiometabolic therapies offer the largest future volume, led by inclisiran, olezarsen, plozasiran and late-stage zilebesiran. Rare neurology and neuromuscular disease will continue to provide premium revenue where genetic selection, severe disease burden and limited alternatives support high treatment value.

The next competitive boundary is delivery beyond the liver. Platforms that achieve reproducible target suppression in the CNS, skeletal muscle, lung and adipose tissue could unlock Alzheimer’s disease, Parkinson’s disease, muscular disorders, pulmonary disease and obesity. Clinical success will depend on whether target knockdown produces durable functional outcomes without introducing monitoring or administration burdens that limit routine use.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 6.81 Billion
Revenue Forecast in 2032	USD 20.93 Billion
Overall Growth Rate	CAGR of 17.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Therapeutic Type	Antisense Oligonucleotides; RNA Interference
By Application	Genetic Disorders; Oncology; Neurodegenerative Diseases; Ophthalmology; Infectious Diseases
By Route of Administration	Intravenous; Subcutaneous; Intrathecal; Others
By End User	Biopharmaceutical Companies; Hospitals; Specialty Clinics; Research Institutes
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Expansion Beyond Rare Diseases	RNA-targeting therapies are moving from orphan indications toward larger cardiovascular, metabolic, neurological, and chronic disease applications, expanding commercial opportunity.
Market Drivers – Growth of RNA Interference Platforms	Advances in GalNAc conjugation, delivery technologies, and longer-duration dosing are accelerating adoption of siRNA therapies across multiple therapeutic areas.
Market Drivers – Increasing Precision Medicine Adoption	Genetic testing, biomarker-driven treatment selection, and targeted disease-modifying approaches are strengthening demand for antisense and RNAi therapeutics.
Market Drivers – Pipeline Expansion and Delivery Innovation	Development of extrahepatic delivery platforms targeting CNS, muscle, adipose tissue, and other organs is creating new market opportunities beyond liver-focused applications.
Customization Option	Available upon request